ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neurogenetics
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1575941
Exploring the causal relationship between plasma proteins and postherpetic neuralgia: a Mendelian randomization study
Provisionally accepted
- Guangxi University of Chinese Medicine, Nanning, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The proteome represents a critical reservoir of potential therapeutic targets for neurological diseases. This study aims to investigate the causal relationship between plasma proteins and postherpetic neuralgia .We performed a two-sample Mendelian Randomization (MR) analysis utilizing genome-wide association study (GWAS) summary statistics from the Decode Genetics dataset (4,907 plasma proteins) and the FinnGen database (490 PHN cases and 435,371 controls). Instrumental variables (IVs) were carefully selected based on stringent criteria to ensure their relevance, independence, and exclusivity. Multiple MR methods, including inverse variance weighting (IVW), MR-Egger, Simple mode, Weighted mode and weighted median, were employed to assess causal relationships. Sensitivity analyses, including leave-one-out analysis, were conducted to confirm the robustness of the findings.Results: Our analysis identified 14 plasma proteins with significant causal associations with PHN,all p ＜ 0.05. Elevated levels of 4 proteins ( NCF1, ATRN, PIANP, CD48) were associated with an increased risk of PHN, while higher levels of 10 proteins ( GABARAPL2, MAP1LC3B, ARF3, KIR2DL5A, DLK1, COLEC12, GPI, SEMG2, EIF4B, HFE2 )were linked to a decreased risk. These findings were supported by sensitivity analyses, which confirmed the robustness of the results and ruled out genetic pleiotropy as a potential bias.This MR study provides strong evidence for the causal role of specific plasma proteins in the development of PHN. These proteins could serve as potential biomarkers and therapeutic targets for PHN. Future research, including randomized controlled trials, is essential to validate these findings and further explore their clinical applicability.
Keywords: Plasma protein, neuropathic pain, postherpetic neuralgia, Mendelian rando mization, Drug Targets
Received: 13 Feb 2025; Accepted: 02 Sep 2025.
Copyright: © 2025 Wei, Yu, Luo, Song, Qin, Li, Sun and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qiuyu Wei, Guangxi University of Chinese Medicine, Nanning, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.